<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34767470</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1549-781X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>59</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Critical reviews in clinical laboratory sciences</Title>
          <ISOAbbreviation>Crit Rev Clin Lab Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Clinical features and diagnostic tools in idiopathic inflammatory myopathies.</ArticleTitle>
        <Pagination>
          <StartPage>219</StartPage>
          <EndPage>240</EndPage>
          <MedlinePgn>219-240</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/10408363.2021.2000584</ELocationID>
        <Abstract>
          <AbstractText>Idiopathic inflammatory myopathies (IIMs) are rare autoimmune disorders affecting primarily muscles, but other organs can be involved. This review describes the clinical features, diagnosis and treatment for IIMs, namely polymyositis (PM), dermatomyositis (DM), sporadic inclusion body myositis (sIBM), immune-mediated necrotizing myopathy (IMNM), and myositis associated with antisynthetase syndrome (ASS). The diagnostic approach has been updated recently based on the discovery of circulating autoantibodies, which has enhanced the management of patients. Currently, validated classification criteria for IIMs allow clinical studies with well-defined sets of patients but diagnostic criteria to guide the care of individual patients in routine clinical practice are still missing. This review analyzes the clinical manifestations and laboratory findings of IIMs, discusses the efficiency of modern and standard methods employed in their workup, and delineates optimal practice for clinical care. Î‘ multidisciplinary diagnostic approach that combines clinical, neurologic and rheumatologic examination, evaluation of electrophysiologic and morphologic muscle characteristics, and assessment of autoantibody immunoassays has been determined to be the preferred approach for effective management of patients with suspected IIMs.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Tsamis</LastName>
            <ForeName>Konstantinos I</ForeName>
            <Initials>KI</Initials>
            <Identifier Source="ORCID">0000-0002-7032-1630</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University Hospital of Ioannina, Ioannina, Greece.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>School of Medicine, European University Cyprus, Nicosia, Cyprus.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Boutsoras</LastName>
            <ForeName>Constantinos</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University Hospital of Ioannina, Ioannina, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kaltsonoudis</LastName>
            <ForeName>Evripidis</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Rheumatology, University Hospital of Ioannina, Ioannina, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pelechas</LastName>
            <ForeName>Eleftherios</ForeName>
            <Initials>E</Initials>
            <Identifier Source="ORCID">0000-0002-9383-5722</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Rheumatology, University Hospital of Ioannina, Ioannina, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nikas</LastName>
            <ForeName>Ilias P</ForeName>
            <Initials>IP</Initials>
            <AffiliationInfo>
              <Affiliation>School of Medicine, European University Cyprus, Nicosia, Cyprus.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Simos</LastName>
            <ForeName>Yannis V</ForeName>
            <Initials>YV</Initials>
            <Identifier Source="ORCID">0000-0003-1764-8906</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Voulgari</LastName>
            <ForeName>Paraskevi V</ForeName>
            <Initials>PV</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Rheumatology, University Hospital of Ioannina, Ioannina, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sarmas</LastName>
            <ForeName>Ioannis</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University Hospital of Ioannina, Ioannina, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Crit Rev Clin Lab Sci</MedlineTA>
        <NlmUniqueID>8914816</NlmUniqueID>
        <ISSNLinking>1040-8363</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009220" MajorTopicYN="Y">Myositis</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Polymyositis (PM)</Keyword>
        <Keyword MajorTopicYN="N">antisynthetase syndrome (ASS)</Keyword>
        <Keyword MajorTopicYN="N">dermatomyositis (DM)</Keyword>
        <Keyword MajorTopicYN="N">immune-mediated necrotizing myopathy (IMNM)</Keyword>
        <Keyword MajorTopicYN="N">sporadic inclusion body myositis (sIBM)</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>12</Day>
          <Hour>17</Hour>
          <Minute>10</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34767470</ArticleId>
        <ArticleId IdType="doi">10.1080/10408363.2021.2000584</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
